Rationale and Design of the IN.PACT BTK Randomized Pilot Study: A Paclitaxel Drug-Coated Balloon vs Standard Percutaneous Transluminal Angioplasty for Infrapopliteal Chronic Total Occlusions

Antonio Micari, MD, PhD1;  Jeffrey J. Popma, MD2;  Francesco Liistro, MD3

Original Contribution

Rationale and Design of the IN.PACT BTK Randomized Pilot Study: A Paclitaxel Drug-Coated Balloon vs Standard Percutaneous Transluminal Angioplasty for Infrapopliteal Chronic Total Occlusions

Antonio Micari, MD, PhD¹; Jeffrey J. Popma, MD²; Francesco Liistro, MD³

Keywords

below the knee

chronic limb-threatening ischemia

Chronic Total Occlusion

Drug-coated balloon

paclitaxel

peripheral artery disease

June 2021

ISSN 2694-3026

Abstract

Objectives. This is a pilot feasibility study and the objective is to evaluate the safety and effectiveness of the investigational device, IN.PACT 014 drug-coated balloon (DCB), compared with standard percutaneous transluminal angioplasty (PTA) in the treatment of patients with chronic limb-threatening ischemia (CLTI) with chronic total occlusions (CTOs) of below-the-knee (BTK) arteries. Methods and Design. The IN.PACT BTK randomized study is a prospective, multicenter, randomized pilot study. Baseline angiography and duplex ultrasonography analyses were performed to confirm that participants met all anatomic and functional eligibility criteria. Successful predilation and strict intraprocedural angiographic and duplex sonographic criteria were conditions of enrollment and randomization. A total of 50 participants were enrolled and randomized 1:1 into DCB (n = 23) or control PTA (n = 27) treatment groups. The primary effectiveness endpoint is late lumen loss at 9 months post procedure. Secondary endpoints include a composite safety endpoint (freedom from device- and procedure-related mortality within 30 days, and freedom from major target-limb amputation and freedom from clinically driven target-lesion revascularization within 9 months after the procedure) and the rate of major adverse events. Participants are being followed through 5 years. All angiographic and duplex ultrasonography images are reviewed by independent core laboratories and all major adverse events are adjudicated by an independent clinical events committee. Discussion and Conclusion. This is a rigorously designed BTK trial in which participant selection and enrollment were a unique aspect, guided by a strict requirement for successful vessel preparation before randomization using explicit angiographic and duplex ultrasound parameters.

J CRIT LIMB ISCHEM 2021;1(2):E35-E44.

Key words: below the knee, chronic limb-threatening ischemia, chronic total occlusion, drug-coated balloon, paclitaxel,
peripheral artery disease

Please Log In To View

Lorem ipsum dolor sit amet consectetur adipiscing elit cras mattis ut suscipit netus dictumst montes facilisi lobortis, dis hac semper non lacus scelerisque risus vel nec nullam posuere etiam leo hendrerit. Diam class aliquet finibus tincidunt netus gravida nullam sollicitudin, semper facilisi consequat litora penatibus at imperdiet taciti arcu, cubilia mollis elit torquent amet congue conubia. Est inceptos accumsan quis neque varius interdum tempor etiam tincidunt, curae condimentum molestie fusce eros himenaeos penatibus magnis convallis, iaculis mattis dictumst mollis facilisi integer porta risus. Efficitur penatibus ad euismod adipiscing et leo consequat luctus, orci nostra mollis rutrum tincidunt curabitur a urna condimentum, felis semper proin molestie vestibulum lectus ac. Lectus libero suscipit donec suspendisse phasellus eleifend habitant tortor, quisque urna taciti sollicitudin sapien magnis sociosqu.

Nostra mus non ante id nascetur neque consectetur porta, habitasse gravida dictumst morbi ex quis arcu senectus, cubilia proin dictum quisque amet eleifend rutrum. Quam nam ridiculus vivamus consequat et convallis interdum orci hendrerit, lacinia platea amet placerat malesuada ligula nostra finibus porta, commodo pretium praesent magna magnis eleifend nunc elit. Nibh dolor sagittis senectus sem etiam ridiculus laoreet finibus vel, elit integer potenti proin ut ultricies orci. Adipiscing ultrices enim curabitur congue efficitur etiam, nec quam ex penatibus fringilla, diam blandit hac risus sed. Habitasse turpis pharetra scelerisque hac sapien integer senectus dictum, taciti suscipit tortor ipsum condimentum ultricies fermentum sodales, facilisi consequat laoreet quis quisque aliquam penatibus. Volutpat hac nunc arcu bibendum aliquet class molestie nostra curae nulla, nam dui cras etiam mollis ut rutrum fermentum in, condimentum nibh vitae ac himenaeos per ullamcorper ultrices scelerisque. Nascetur cubilia natoque suspendisse nostra gravida lobortis viverra pretium metus, quisque inceptos sit ante dolor phasellus netus neque, turpis lacinia tortor nam magnis potenti hac elit. Donec malesuada laoreet integer himenaeos velit auctor justo suspendisse, potenti class facilisi etiam fusce torquent fermentum adipiscing et, viverra vivamus sociosqu ac parturient dui leo. Etiam vel senectus duis rhoncus suscipit enim urna ligula, morbi dictumst a adipiscing laoreet consequat aptent at aliquam, imperdiet augue et iaculis egestas pellentesque justo.

Mollis nulla sociosqu feugiat sagittis risus fringilla nunc mattis donec viverra, nullam arcu auctor consectetur maecenas lectus netus tortor odio aptent, ac leo montes primis condimentum ornare libero senectus imperdiet. Ridiculus aptent pellentesque quam efficitur bibendum ultricies mi, finibus accumsan scelerisque himenaeos lacinia metus integer rutrum, curabitur dapibus ac amet a non. Viverra cubilia fames velit eleifend quam fusce tincidunt ac magna turpis, eu phasellus nisi pretium sodales nullam nascetur ipsum. Tellus platea ipsum mus laoreet ante libero habitasse nam cubilia lacinia interdum quis eleifend curabitur torquent pretium, euismod fringilla commodo per fermentum condimentum arcu eros id praesent erat magna ullamcorper nostra faucibus. Proin sagittis nullam curae nam etiam sapien nibh, aliquam praesent elit imperdiet risus ipsum nunc, aliquet cras sociosqu netus arcu ultrices. Pulvinar cursus luctus eget ex quisque dictum lacus, commodo varius hendrerit nunc facilisi lorem efficitur habitasse, pellentesque ad sapien iaculis nec egestas. Curabitur vitae etiam dis id finibus ipsum nascetur dignissim vestibulum, integer convallis consequat nec proin aptent cursus imperdiet neque, et ante feugiat morbi curae blandit fringilla torquent.

Velit consectetur dictumst vestibulum aliquet elit porttitor, per himenaeos condimentum urna scelerisque eleifend dolor, ac ultrices torquent cras tortor duis, et vel rutrum orci habitant. Eleifend netus aptent cursus laoreet phasellus vel platea porta lorem a conubia, vitae magna erat sodales aliquam mus amet dignissim feugiat posuere. Varius aliquam feugiat erat suspendisse lectus egestas odio blandit vestibulum auctor lacinia, imperdiet lobortis porta nam rhoncus morbi ipsum elit taciti placerat sociosqu, dictum nascetur posuere vel non primis parturient laoreet ligula metus. A ultrices facilisi nam pellentesque class natoque aliquet, elit sed himenaeos senectus sodales dignissim et potenti, tempus fringilla platea netus placerat donec. Vestibulum platea nulla scelerisque elit malesuada himenaeos metus fames tempor ipsum, hac dictumst eros lobortis rutrum turpis molestie nascetur mus torquent, etiam ornare proin arcu hendrerit lacinia taciti diam ligula. Lectus conubia tellus enim mattis nam ex habitasse parturient pharetra erat, lorem fusce elit dui gravida viverra convallis tortor quam at, efficitur imperdiet rhoncus vivamus scelerisque etiam placerat magnis eros. Magna euismod morbi risus dolor donec odio volutpat at, sollicitudin dui faucibus velit quisque netus id, rhoncus vivamus mus senectus tincidunt curabitur varius. Iaculis non vitae himenaeos arcu quam elit habitant, in suscipit aenean habitasse vestibulum vel efficitur, ultricies facilisi sem posuere penatibus torquent.

References

1. Gray BH, Diaz-Sandoval LJ, Dieter RS, et al. SCAI expert consensus statement for infrapopliteal arterial intervention appropriate use. Catheter Cardiovasc Interv. 2014;84:539-445.

2. Gentile F, Lundberg G, Hultgren R. Outcome for endovascular and open procedures in infrapopliteal lesions for critical limb ischemia: registry based single center study. Eur J Vasc Endovasc Surg. 2016;52:643-649.

3. Giles KA, Pomposelli FB, Spence TL, et al. Infrapopliteal angioplasty for critical limb ischemia: relation of TransAtlantic InterSociety Consensus class to outcome in 176 limbs. J Vasc Surg. 2008;48:128-136.

4. Patel SD, Biasi L, Paraskevopoulos I, et al. Comparison of angioplasty and bypass surgery for critical limb ischaemia in patients with infrapopliteal peripheral artery disease. Br J Surg. 2016;103:1815-1822.

5. Popplewell MA, Davies HOB, Narayanswami J, et al. A comparison of outcomes in patients with infrapopliteal disease randomised to vein bypass or plain balloon angioplasty in the bypass vs angioplasty in severe ischaemia of the leg (BASIL) trial. Eur J Vasc Endovasc Surg. 2017;54:195-201.

6. Bosiers M, Scheinert D, Peeters P, et al. Randomized comparison of everolimus-eluting versus bare-metal stents in patients with critical limb ischemia and infrapopliteal arterial occlusive disease. J Vasc Surg. 2012;55:390-398.

7. Rastan A, Brechtel K, Krankenberg H, et al. Sirolimus-eluting stents for treatment of infrapopliteal arteries reduce clinical event rate compared to bare-metal stents: long-term results from a randomized trial. J Am Coll Cardiol. 2012;60:587-591.

8. Rastan A, Tepe G, Krankenberg H, et al. Sirolimus-eluting stents vs bare-metal stents for treatment of focal lesions in infrapopliteal arteries: a double-blind, multi-centre, randomized clinical trial. Eur Heart J. 2011;32:2274-2281.

9. Scheinert D, Katsanos K, Zeller T, et al. A prospective randomized multicenter comparison of balloon angioplasty and infrapopliteal stenting with the sirolimus-eluting stent in patients with ischemic peripheral arterial disease: 1-year results from the ACHILLES trial. J Am Coll Cardiol. 2012;60:2290-2295.

10. Fanelli F, Cannavale A, Corona M, Lucatelli P, Wlderk A, Salvatori FM. The “REBELLUM” — lower limb multilevel treatment with drug eluting balloon — randomized trial: 1-year results. J Cardiovasc Surg (Torino). 2014;55:207-216.

11. Liistro F, Porto I, Angioli P, et al. Drug-eluting balloon in peripheral intervention for below the knee angioplasty evaluation (DEBATE-BTK): a randomized trial in diabetic patients with critical limb ischemia. Circulation. 2013;128:615-621.

12. Mustapha JA, Brodmann M, Geraghty PJ, et al. Drug-coated vs uncoated percutaneous transluminal angioplasty in infrapopliteal arteries: six-month results of the Lutonix BTK trial. J Invasive Cardiol. 2019;31:205-211.

13. Siablis D, Kitrou PM, Spiliopoulos S, Katsanos K, Karnabatidis D. Paclitaxel-coated balloon angioplasty versus drug-eluting stenting for the treatment of infrapopliteal long-segment arterial occlusive disease: the IDEAS randomized controlled trial. JACC Cardiovasc Interv. 2014;7:1048-1056.

14. Zeller T, Baumgartner I, Scheinert D, et al. Drug-eluting balloon versus standard balloon angioplasty for infrapopliteal arterial revascularization in critical limb ischemia: 12-month results from the IN.PACT DEEP randomized trial. J Am Coll Cardiol. 2014;64:1568-1576.

15. Zeller T, Beschorner U, Pilger E, et al. Paclitaxel-coated balloon in infrapopliteal arteries: 12-month results from the BIOLUX P-II randomized trial (Biotronik’s first in man study of the Passeo-18 Lux drug-releasing PTA balloon catheter vs the uncoated Passeo-18 PTA balloon catheter in subjects requiring revascularization of infrapopliteal arteries). JACC Cardiovasc Interv. 2015;8:1614-1622.

16. Ozpak B, Bozok S, Cayir MC. Thirty-six-month outcomes of drug-eluting balloon angioplasty in the infrapopliteal arteries. Vascular. 2018;26:457-463.

17. Thabane L, Ma J, Chu R, et al. A tutorial on pilot studies: the what, why and how. BMC Med Res Methodol. 2010;10:1.

18. Brodmann M, Werner M, Meyer DR, et al. Sustainable antirestenosis effect with a low-dose drug-coated balloon: the ILLUMENATE European randomized clinical trial 2-year results. JACC Cardiovasc Interv. 2018;11:2357-2364.

19. Chen Z, Guo W, Jiang W, et al. IN.PACT SFA clinical study using the IN.PACT Admiral drug-coated balloon in a Chinese patient population. J Endovasc Ther. 2019;26:471-478.

20. Iida O, Soga Y, Urasawa K, et al. Drug-coated balloon vs standard percutaneous transluminal angioplasty for the treatment of atherosclerotic lesions in the superficial femoral and proximal popliteal arteries: one-year results of the MDT-2113 SFA Japan randomized trial. J Endovasc Ther. 2018;25:109-117.

21. Iida O, Soga Y, Urasawa K, et al. Drug-coated balloon versus uncoated percutaneous transluminal angioplasty for the treatment of atherosclerotic lesions in the superficial femoral and proximal popliteal artery: 2-year results of the MDT-2113 SFA Japan randomized trial. Catheter Cardiovasc Interv. 2019;93:664-672.

22. Krishnan P, Faries P, Niazi K, et al. Stellarex drug-coated balloon for treatment of femoropopliteal disease: twelve-month outcomes from the randomized ILLUMENATE pivotal and pharmacokinetic studies. Circulation. 2017;136:1102-1113.

23. Laird JA, Schneider PA, Jaff MR, et al. Long-term clinical effectiveness of a drug-coated balloon for the treatment of femoropopliteal lesions. Circ Cardiovasc Interv. 2019;12:e007702.

24. Laird JR, Schneider PA, Tepe G, et al. Durability of treatment effect using a drug-coated balloon for femoropopliteal lesions: 24-month results of IN.PACT SFA. J Am Coll Cardiol. 2015;66:2329-2338.

25. Micari A, Brodmann M, Keirse K, et al. Drug-coated balloon treatment of femoropopliteal lesions for patients with intermittent claudication and ischemic rest pain: 2-year results from the IN.PACT global study. JACC Cardiovasc Interv. 2018;11:945-953.

26. Rosenfield K, Jaff MR, White CJ, et al. Trial of a paclitaxel-coated balloon for femoropopliteal artery disease. N Engl J Med. 2015;373:145-153.

27. Schneider PA, Laird JR, Tepe G, et al. Treatment effect of drug-coated balloons is durable to 3 years in the femoropopliteal arteries: long-term results of the IN.PACT SFA randomized trial. Circ Cardiovasc Interv. 2018;11:e005891.

28. Schroe H, Holden AH, Goueffic Y, et al. Stellarex drug-coated balloon for treatment of femoropopliteal arterial disease — the ILLUMENATE global study: 12-month results from a prospective, multicenter, single-arm study. Catheter Cardiovasc Interv. 2018;91:497-504.

29. Schroeder H, Werner M, Meyer DR, et al. Low-dose paclitaxel-coated versus uncoated percutaneous transluminal balloon angioplasty for femoropopliteal peripheral artery disease: one-year results of the ILLUMENATE European randomized clinical trial (randomized trial of a novel paclitaxel-coated percutaneous angioplasty balloon). Circulation. 2017;135:2227-2236.

30. Tepe G, Laird J, Schneider P, et al. Drug-coated balloon versus standard percutaneous transluminal angioplasty for the treatment of superficial femoral and popliteal peripheral artery disease: 12-month results from the IN.PACT SFA randomized trial. Circulation. 2015;131:495-502.

31. Tepe G, Schnorr B, Albrecht T, et al. Angioplasty of femoral-popliteal arteries with drug-coated balloons: 5-year follow-up of the THUNDER trial. JACC Cardiovasc Interv. 2015;8:102-108.

32. Zeller T, Brodmann M, Micari A, et al. Drug-coated balloon treatment of femoropopliteal lesions for patients with intermittent claudication and ischemic rest pain. Circ Cardiovasc Interv. 2019;12:e007730.

33. Byrne RA, Joner M, Alfonso F, Kastrati A. Drug-coated balloon therapy in coronary and peripheral artery disease. Nat Rev Cardiol. 2014;11:13-23.

34. Fanelli F, Cannavale A, Boatta E, et al. Lower limb multilevel treatment with drug-eluting balloons: 6-month results from the DEBELLUM randomized trial. J Endovasc Ther. 2012;19:571-580.

35. Zeller T, Baumgartner I, Scheinert D, et al. IN.PACT Amphirion paclitaxel-eluting balloon versus standard percutaneous transluminal angioplasty for infrapopliteal revascularization of critical limb ischemia: rationale and protocol for an ongoing randomized controlled trial. Trials. 2014;15:63.

36. Spreen MI, Gremmels H, Teraa M, et al. Diabetes is associated with decreased limb survival in patients with critical limb ischemia: pooled data from two randomized controlled trials. Diabetes Care. 2016;39:2058-2064.

Affiliations and Disclosures